ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Chronic lung allograft dysfunction (CLAD) phenotypes

Chronic lung allograft dysfunction (CLAD) phenotypes
ISHLT classification Spirometry Lung volumes Chest CT findings*
BOS

FEV1 ≤80% baseline

FEV1/FVC <0.7		 TLC >90% baseline No persistent opacities or fibrotic changes
RAS

FEV1 ≤80% baseline

FEV1/FVC >0.7		 TLC <90% baseline Persistent opacities or fibrotic changes
Mixed

FEV1 ≤80% baseline

FEV1/FVC <0.7		 TLC <90% baseline Persistent opacities or fibrotic changes
Undefined

FEV1 ≤80% baseline

FEV1/FVC <0.7		 TLC >90% baseline Persistent opacities or fibrotic changes
Undefined

FEV1 ≤80% baseline

FEV1/FVC <0.7		 TLC <90% baseline No persistent opacities or fibrotic changes
Unclassified FEV1 ≤80% baseline and any other pattern FEV1 ≤80% baseline and any other pattern FEV1 ≤80% baseline and any other pattern
Phenotypes of CLAD based on spirometry, lung volumes, and CT findings. Baseline refers to the posttransplant baseline spirometry and lung volumes; for FEV1, this is defined as the average of the two maximal posttransplant FEV1 values (performed at least three weeks apart). The TLC baseline should be the posttransplant TLC associated with baseline FEV1. Please refer to UpToDate content on CLAD for additional information.

CLAD: chronic lung allograft dysfunction; ISHLT: International Society for Heart and Lung Transplantation; CT: computed tomography; BOS: bronchiolitis obliterans syndrome; RAS: restrictive allograft syndrome; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; TLC: total lung capacity.

* For the purposes of CLAD phenotyping, CT findings of concern are persistent (lasting greater than three months) reticulations, ground-glass opacities, or consolidations consistent with possible fibrosis. New persistent pleural thickening is also a qualifying feature.

Adapted from: Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant 2019; 38:493.

Additional data from: Levy L, Huszti E, Renaud-Picard B, et al. Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system. J Heart Lung Transplant 2020; 39:761.
Graphic 141258 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟